Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 8/20 | 0.46 |
| ▸ | MAOA | P21397 | 4/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175037 | 0.91 | SCD5 (0.53) | SCD5KDM1AHCRTR1HCRTR2SCN9A | |
| SCHEMBL4166426 | 0.82 | DPP4 (0.47) | DPP4DPP8DPP9DPP7SCD5 | |
| SCHEMBL4172971 | 0.80 | TRPC3 (0.44) | SCD5HCRTR1HCRTR2SCN9ACYP3A4 | |
| SCHEMBL3169619 | 0.80 | SCN9A (0.54) | SCN9A | |
| SCHEMBL4183923 | 0.80 | TRPC3 (0.47) | SCD5SCN9A | |
| SCHEMBL4180040 | 0.79 | TRPC3 (0.44) | SCD5SCN9A | |
| SCHEMBL4172599 | 0.78 | TRPC3 (0.61) | SCD5SCN9A | |
| SCHEMBL4177686 | 0.78 | SCN9A (0.51) | KDM1AMAOASCN9A | |
| SCHEMBL4180047 | 0.78 | TRPC3 (0.47) | SCD5SCN9A | |
| SCHEMBL4184719 | 0.77 | ALDH1A1 (0.40) | SCD5KDM1ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | DPP4 2184/4885DPP8 3044/4885DPP9 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.